Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
Public ClinicalTrials.gov record NCT00141323. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PEARL: Postmenopausal Evaluation And Risk-Reduction With Lasofoxifene
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
Study identification
- NCT ID
- NCT00141323
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 8,556 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years to 80 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2001 (Type not available)
- Primary completion
- Dec 2007 (Actual)
- Completion
- Dec 2007 (Actual)
- Last update posted
- Aug 15, 2011
2001 – 2007
United States locations
- U.S. sites
- 48
- U.S. states
- 16
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35205 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35216 | — |
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | La Jolla | California | 92093-0659 | — |
| Pfizer Investigational Site | La Jolla | California | 92161 | — |
| Pfizer Investigational Site | Palm Desert | California | 92260 | — |
| Pfizer Investigational Site | Palm Springs | California | 92262 | — |
| Pfizer Investigational Site | Palm Springs | California | 92263 | — |
| Pfizer Investigational Site | Poway | California | 94064 | — |
| Pfizer Investigational Site | Rancho Mirage | California | 92270 | — |
| Pfizer Investigational Site | San Diego | California | 92123 | — |
| Pfizer Investigational Site | San Diego | California | 92128 | — |
| Pfizer Investigational Site | Brandon | Florida | 33611 | — |
| Pfizer Investigational Site | Leesburg | Florida | 34748 | — |
| Pfizer Investigational Site | Tampa | Florida | 33607 | — |
| Pfizer Investigational Site | Tampa | Florida | 33613 | — |
| Pfizer Investigational Site | Tampa | Florida | 33614 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33414 | — |
| Pfizer Investigational Site | Des Plaines | Illinois | 60016 | — |
| Pfizer Investigational Site | Morton Grove | Illinois | 60053 | — |
| Pfizer Investigational Site | Des Moines | Iowa | 50309 | — |
| Pfizer Investigational Site | Bethesda | Maryland | 20817 | — |
| Pfizer Investigational Site | Montgomery Village | Maryland | 20886 | — |
| Pfizer Investigational Site | Arden Hills | Minnesota | 55112 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55415-1226 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68131 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87102 | — |
| Pfizer Investigational Site | Albuquerque | New Mexico | 87106 | — |
| Pfizer Investigational Site | Centerville | Ohio | 45459 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45409 | — |
| Pfizer Investigational Site | Portland | Oregon | 97239 | — |
| Pfizer Investigational Site | Charleroia | Pennsylvania | 15022 | — |
| Pfizer Investigational Site | Monessen | Pennsylvania | 15062 | — |
| Pfizer Investigational Site | Cordova | Tennessee | 38018 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38119 | — |
| Pfizer Investigational Site | Dallas | Texas | 75230 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23225 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23227 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23229 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23235 | — |
| Pfizer Investigational Site | Redmond | Washington | 98052 | — |
| Pfizer Investigational Site | Seattle | Washington | 98101-1448 | — |
| Pfizer Investigational Site | Seattle | Washington | 98104 | — |
| Pfizer Investigational Site | Seattle | Washington | 98105-4631 | — |
| Pfizer Investigational Site | Seattle | Washington | 98112 | — |
| Pfizer Investigational Site | Seattle | Washington | 98133 | — |
| Pfizer Investigational Site | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 153 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00141323, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2011 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00141323 live on ClinicalTrials.gov.